The similarity in the TIME for HER2-positive and TNBC tumors suggests that patients with HER2-positive BC could also benefit from immunotherapy combined with established or novel HER2-targeted therapy, e.g. trastuzumab emtansine (T-DM1). Here, ERBB2 is linked to breast cancer.